AstraZeneca News
Prices
Here are all todays headlines related to AstraZeneca News. If you wish to drill deeper to view past AstraZeneca News items, follow the next 20 headlines link at the foot of the page.
06-06-2019
An AstraZeneca PLC (LON:AZN) drug being developed chronic lymphocytic leukaemia has successfully navigated a phase III clinical trial. AZ’s Calquence, to use the jargon, demonstrated a ...
21-05-2019
This article is written for those who want to get better at using price to earnings ratios (P/E ratios). We'll apply a basic P/E ratio analysis to AstraZeneca PLC's (LON:AZN), to help you decide ...
01-05-2019
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Does the May share price for AstraZeneca PLC (LON:AZN) reflect what it's ...
19-04-2019
Goldman Sachs Group set a GBX 5,000 ($65.33) target price on AstraZeneca (LON:AZN) in a research report released on Wednesday, April 3rd, Borsen Zeitung reports. The firm currently has a sell rating ...
02-04-2019
Complete the form below to receive the latest headlines and analysts' recommendations for AstraZeneca with our free daily email newsletter: AstraZeneca (LON:AZN) has been given a GBX 5,180 ($67.69) ...
26-03-2019
AstraZeneca (LON:AZN)‘s stock had its “sell” rating reissued by equities research analysts at Goldman Sachs Group in a research note issued to investors on Monday, March 18th. Other analysts also ...
14-02-2019
Complete the form below to receive the latest headlines and analysts' recommendations for AstraZeneca with our free daily email newsletter: AstraZeneca plc (LON:AZN) shares shot up 5.1% on Thursday fo...
14-12-2018
Today, Morgan Stanley raised its price target on AstraZeneca plc (LON:AZN) to GBX 6,400 per share. There are 11 Buy Ratings, 8 Hold Ratings, 2 Sell Ratings, no Strong Buy Ratings on the stock.
03-12-2018
AstraZeneca (LON:AZN) has wrapped up the divestment of some rights to Nexium and Vimovo, the blue-chip pharmco has said. The deal, announced in October, is part of the Anglo-Swedish drugmaker’s ...
19-11-2018
AstraZeneca (LON:AZN) has begun succession planning for its chief executive Pascal Soriot, following shareholder pressure, The Sunday times has revealed. The news comes after the Anglo-Swedish ...
12-11-2018
Shares in AstraZeneca (LON:AZN) have climbed higher in London in today’s session following upbeat trial results for its diabetes treatment Farxiga, and as the company said that one of its ...
08-11-2018
Shares in AstraZeneca (LON:AZN) have climbed higher in London this morning, as the company delivered a rise in product sales for the third quarter of the year. The company, which is betting on its ...
30-10-2018
AstraZeneca PLC (LON:AZN) has sold off the rights to two of its drugs for almost US$1bn to Grünenthal – the German pharma giant which first developed and sold thalidomide. FTSE 100-listed Astra is sel...
24-10-2018
Liberum Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note released on Tuesday morning. A number of other research firms have also weighed in on AZN. JPMorgan C...
22-10-2018
A late-stage trial has showed that AstraZeneca’s (LON:AZN) oncology treatment Lynparza cut risk of disease progression or death by 70 percent in patients with newly-diagnosed, advanced BRCA ...
16-10-2018
AstraZeneca’s (LON:AZN) chairman has said that the blue-chip drugmaker will keep a freeze on manufacturing investments in the UK in the case of a lack of clarity over the country’s exit from ...
20-06-2018
SSE: RBC Capital Markets downgrades to sector perform with a target price of 1,350p.
20-06-2018
With Astrazeneca the strongest consensus 'buy' in the sector, broker Liberum has told concerned clients why it only rates the shares at 'hold' rating since late last year, though it upped the share price target to £53 from £50.
19-06-2018
US pharma businesses have warned the government that the UK's dominant position in life sciences is threatened by Brexit and the NHS's slow adoption of new medicines.
12-06-2018
AstraZeneca, alongside its partner Eli Lilly and Company, announced on Tuesday the discontinuation of the global Phase III clinical trials of lanabecestat, an oral beta secretase cleaving enzyme (BACE) inhibitor, for the treatment of Alzheimer's disease.
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
| Enter share symbol |
| Search share prices A to Z |
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- RBS share price
- Diageo share price
- Standard Life Share Price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- Morrisons Share Price
- Aviva Share Price
- ASOS Share price
- RPT Share Price
- SXX Share Price
- Easyjet Share Price
- Next Share Price
- Thomas Cook Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- Greene King Share Price
- Marstons share price
- NUOG share price
- UKOG share price
- SOLG share price